ARTICLE BY LOUIS
What’s A “Biopharma CDMO”?
In part two of my exclusive interview with Phlow Corporation's CEO Dr. Eric Edwards, we turn our attention to biopharma business models and CDMO partnerships.
You Don’t Know Phlow: The Backstory Of A Misread Biopharma Start-Up
No biopharma start-up has been as misconstrued, hastily judged in strategy and capability, or even labeled “political.” Now Phlow Corporation’s CEO Eric Edwards sets the record straight in an exclusive interview.
Is PhRMA’s White House Rebuttal Acceptable?
While the biopharmaceutical industry can only be commended for the work underway to bring the world vaccines and therapies to halt the spread and severity of COVID-19, it would be ironic if PhRMA uses the pandemic as leverage to maintain the drug supply-chain status quo.
A Word From Germany On U.S. Manufacturing Productivity
Of 367 production plants BASF operates worldwide, six are Verbund sites. Those six produce more than 50% of all BASF volumes. A CEO of a U.S.-based CDMO thinks Verbund is the kind of thinking needed at drug development and manufacturing facilities in this country.
Why You Need People Like Jana Spes At Your Company
Industry veteran Jana Spes provides some uniquely qualified analysis and guidance on the outsourcing industry and working with CDMOs. Don’t be surprised if you come away thinking for your next outsourcing operations hire, specialization is out, and the Spes model is in.
Award-Winning Questions: “Who Are We?” And “Who Are They?”
Outsourcing Pharma Chief Editor Louis Garguilo explains what you can expect from this year’s CMO Awards publication and how it can help you when choosing an outsourcing partner.
When Employees Become The Supply Chain: Leadership In A Pandemic
With your newly dispersed workforce, employees have in effect become a part of your external supply chain. How can leaders help them get through this time of uncertainty, and continue to perform at a high level? Here's some advice.
3 Questions Of Risk And Communication In A Time Of Coronavirus
Communication with your service providers may turn out most important in getting through immediate coronavirus-induced supply-chain challenges. Outsourcing may have got you into this situation; now it may be the only thing that can get you out.
Sign It, President Trump; Don’t Go There, President Xi
If drugs are discovered as purposefully held up by China to create a supply issue in the U.S., would you ever again employ a China-based CMO? Who would have thought Outsourced Pharma readers would be front and center in presidential politics? But you are.
Don’t Spread The Wrong Message: COVID-19 And Respect For CMOs
The first was to be a celebration for safely, reliably, and productively keeping drug development and manufacturing supply chains running. The second is a threat to shut those supply chains down. But here’s a second irony: This new coronavirus may have provided us an opportunity of sorts.